Journal
DIABETES OBESITY & METABOLISM
Volume 16, Issue 10, Pages 885-890Publisher
WILEY
DOI: 10.1111/dom.12280
Keywords
metformin; sulphonylureas; type 2 diabetes
Categories
Funding
- Cardiff University
- Abbott
- ALK
- Astellas
- Diabetes UK
- Engineering and Physical Sciences Research Council
- EASFD
- Ferring
- GSK
- Jenson (Internis)
- Lilly
- Medical Research Council
- Medtronic
- MSD
- National Health Service
- Norgine
- Pfizer
- Sanofi-Aventis
- Shire
- Wyeth
Ask authors/readers for more resources
Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available